Metagenomi Therapeutics reported second quarter 2026 financial results and business updates. The company held $120.7 million in cash, cash equivalents, and available-for-sale marketable securities as of June 30, 2026, with a runway supporting operations through the fourth quarter of 2027. Research and development expenses were $22.5 million for the quarter, while general and administrative expenses decreased to $6.0 million from $7.0 million in the prior year period. The company reported a net loss of $27.48 million, or $0.73 per share. Metagenomi remains on track to submit an investigational new drug application for its MGX-001 hemophilia A program in the fourth quarter of 2026 and expects IND-enabling studies to be complete by the end of the third quarter. The company operates as an in vivo genome editing firm developing curative genetic medicines.

On June 9, 2026, Brian C. Thomas, Ph.D. resigned from the Board of Directors of Metagenomi Therapeutics, Inc. Dr. Thomas's resignation was not due to any disagreement with the company's operations, policies, or practices. Additionally, the company's 2026 annual meeting of stockholders, held virtually, resulted in the following election of Class II Directors, Juergen Eckhardt, M.D., M.B.A. and Eric Bjerkholt, M.B.A., to serve until 2029. Metagenomi Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions.